Investment Thesis
Olema is a pre-commercial pharmaceutical company with no revenue and significant annual operating cash burn of $46M, consuming approximately 1.1 years of available cash reserves. While the balance sheet is strong with $480.5M equity, zero debt, and excellent liquidity, the company remains dependent on uncertain clinical development and regulatory approval with no visible near-term revenue catalysts. The improving loss trajectory (25.5% YoY improvement) is encouraging but insufficient to offset the fundamental challenges inherent in pre-revenue biotech.
Strengths
- Exceptional balance sheet strength with $480.5M stockholders equity and zero long-term debt
- Outstanding liquidity position with 10.88x current ratio and minimal near-term financing pressure
- Improving loss trajectory with net income declining 25.5% YoY and EPS improving 15.0% YoY, indicating cost management progress
Risks
- No revenue generation - entirely pre-commercial with success dependent on pipeline clinical development outcomes
- Limited cash runway of approximately 1.1 years at current $46M annual operating cash burn, requiring future funding or clinical success
- High regulatory and clinical development risk typical of early-stage biotech with no approved commercial products or revenue diversification
Key Metrics to Watch
- Quarterly cash burn rate and path to achieving positive operating cash flow or revenue milestone
- Clinical trial advancement, FDA interactions, regulatory milestones, and competitive pipeline developments
Financial Metrics
Revenue
N/A
Net Income
-53.1M
EPS (Diluted)
$-0.52
Free Cash Flow
-46.0M
Total Assets
530.6M
Cash
52.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-11.0%
ROA
-10.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
10.88x
Quick Ratio
10.88x
Debt/Equity
0.00x
Debt/Assets
9.5%
Interest Coverage
-88.80x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T08:56:27.161786 |
Data as of: 2026-03-31 |
Powered by Claude AI